RTX

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✓

Return

+0.90%

Status

scored

Maintain RTX existing exposure without fresh capital deployment, as the binding 9/29 lesson explicitly prohibits T1 entry when stacked overhead resistance (10 EMA $185.43, 200 SMA $193.93, 50 SMA $203.71), negative MACD (-5.46/-5.35), and Q3 earnings within ~3 weeks all align. Bottoming signals (RSI divergence 19→32, Bollinger lower-band tag at $179.02, MACD histogram compression) are real but serve as confirmation prerequisites, not entry triggers. Pre-committed re-engagement triggers and 60-90 DTE put hedges at $170-175 strikes preserve asymmetric optionality while avoiding the 9/29 and 10/06 binding failure modes.

Outcome

✗

Return

+2.25%

Status

scored

Maintain RTX at HOLD with pre-committed triggers, neither adding nor trimming. The 10/06 binding lesson explicitly overrides the prior SELL (selling at the oversold extreme violated the thesis's own identification of fear-driven flush), while the 9/29 lesson prohibits T1 deployment with stacked overhead resistance, negative MACD, and imminent binary earnings. Hedge with 60-90 DTE puts at $170-175 strikes, hard stop at $175; upgrade trigger is confirmed close above $185.67 on above-average volume with MACD bullish cross.

Outcome

✓

Return

-1.65%

Status

scored

Execute full exit of the remaining 20-28% residual RTX position ahead of the Q3 2026 earnings binary catalyst (~3 weeks out). All three binding trigger conditions from the 10/05 reflection are satisfied: binary catalyst within 30 days (38% EPS growth bar at 23.5x forward P/E), technicals as damaged as 10/05 (RSI 22.42, broken 200 SMA at $193.89, negative MACD, price below $180.99 lower Bollinger band), and structural floor-attenuation constraint explicitly de-weighted per the 10/05 update. The cumulative empirical record across 9/29, 9/30, 10/01, 10/02, and 10/05 is unambiguous: every decision at this configuration has bled alpha, with Holds producing -0.4% to -1.8% alpha decay. Trim proceeds parked in short-duration Treasuries pending pre-committed re-engagement triggers.

Outcome

✓

Return

-0.56%

Status

scored

Execute a decisive 50-55% trim of the current 48-55% residual position via two-tranche execution, bringing residual exposure to 20-28% of original position ahead of Q3 2026 binary catalyst. The binding 10/02 reflection is dispositive on this configuration; both the Research Manager's Overweight and Trader's Buy proposals are rejected as they invert the binding lesson at the exact configuration it was written to address. Standalone Underweight with 20-28% residual preserves meaningful structural thesis exposure while decisively escaping the alpha-decaying bucket.

Outcome

✓

Return

-0.19%

Status

scored

Execute a decisive 35-40% trim of the 80-85% RTX residual position via two tranches—Tranche 1 (~15-18%) immediately at $184.68 and Tranche 2 (~17-22%) as limit orders at $188-190—reducing exposure to 48-55% of original position ahead of the Q3 2026 binary catalyst. Reject the Hold recommendation based on five+ consecutive Holds that decayed -0.4% to -1.8% alpha; the 10/01 reflection bindingly prescribes the 35-40% trim zone when overhead resistance and imminent catalysts stack simultaneously, as they do now with all major moving averages overhead and earnings ~30 days out.

Outcome

–

Return

-0.18%

Status

scored

RTX Portfolio Manager maintains UNDERWEIGHT with a binding directive to trim 25-30% of the 80-85% residual position via two tranches (10-12% immediate at $185-187, 13-18% limit orders at $190-193), reducing exposure to 50-60% of original. The decision explicitly rejects both the Research Manager's Overweight (50% new-money deployment) and the trader's Buy ($185 entry, $180.20 stop), citing the 9/29/2026 empirical record where an identical configuration produced -0.5% alpha, and the documented Hold bucket decay of -0.4% to -1.8% across six prior decisions.

Outcome

✓

Return

-0.34%

Status

scored

Maintain RTX at 80-85% residual exposure as the binding HOLD decision, with explicit prohibition on adding at $185.65 due to stacked overhead resistance ($193.75 200 SMA), 21-session negative MACD, and Q3 2026 earnings within ~4 weeks—all three conditions from the 9/29 binding reflection are present. Pre-committed triggers govern re-entry: escalate to Underweight with 25-30% trim on confirmed close <$184.54 with volume >3.5M; tactical add back to 90-95% of pre-trim size on confirmed close >$193.75 with volume >3.5M and RSI >40; hard stop at $178.50 below lower Bollinger Band extension.

Outcome

–

Return

-0.69%

Status

scored

Initiate a measured 1.5% portfolio addition in RTX via three-tranche staged deployment (0.5% immediate at $186-188, 0.5% at $180-182 flush, 0.5% on 200-SMA reclaim at $193.70 with RSI>40 and volume>3.5M), with hard stop at $178.50 and price target of $215-225. This OVERWEIGHT rating explicitly breaks the five-consecutive-Hold pattern, acknowledging Q2 2026 fundamental acceleration (margin expansion to 11.4%, FCF inflection to $9.88B, $289B backlog) while respecting stacked bearish technicals and binary Q3 earnings risk in ~4 weeks.

Outcome

–

Return

-0.38%

Status

scored

Execute a 25-30% tactical trim of RTX via two tranches: Tranche 1 (~10%) at $187.66 and Tranche 2 (~15-20%) as limit orders at $193-195, with a hard stop at $181.50 on the remaining 70-75% position. Re-engagement requires confirmed close above $193.63 with RSI>40 and positive MACD histogram cross, or alternatively a deep-value reload if price flushes to $176-180 with RSI sub-30 bullish divergence and stabilizing macro conditions. The 4-8 week tactical horizon into Q3 2026 earnings preserves exposure to the $289B backlog conversion and margin expansion thesis while avoiding the documented alpha-decay pattern of pure Holds at this technical configuration.

Outcome

–

Return

-0.92%

Status

scored

Trim 30-35% of RTX via two-tranche execution: ~15% immediately at $189.40-190.50, then 15-20% into the $193-195 resistance zone. Hard stop at $196.50 on remaining position, with residual floor stop at $186 close-confirmation. No new capital allocation until daily close above $193.54 with RSI>40 and positive MACD histogram cross.

Outcome

–

Return

+0.42%

Status

scored

Execute a 10-15% tactical trim of RTX exposure (50% immediately at ~$188, 50% on bounce to $194-197 over 3-5 sessions) to convert a fifth consecutive alpha-decaying Hold into measurable tactical positioning, while preserving 85-90% residual structural exposure to the $289B backlog and FCF inflection. Hard stop at $186 close below lower Bollinger Band, with three re-engagement paths: deep-value reload at $170-175 with RSI sub-30, upgrade to Hold above $207.50 on volume >4M, or modest 10% add on bounce to $194-197 with volume >5M and RSI reclaiming 35.

Outcome

✗

Return

-1.86%

Status

scored

Maintain RTX at 80-85% residual exposure with no fresh capital commitment and no further trimming. Tighten protective stop to $188 (just below lower Bollinger at $187.45). Pre-commit a 15% scale-in at $185 only if all three capitulation triggers fire simultaneously (price + RSI sub-25 + volume >8M shares) within a 10-session window; pre-commit a 10% tactical add on confirmed close >$196 with above-average volume and RSI >40. Downgrade to Underweight with 15% trim on confirmed daily close <$188. Time horizon: 4-8 weeks tactical into Q3 2026 earnings and macro resolution; 3-6 months for full structural thesis reassessment.

Outcome

✗

Return

+0.63%

Status

scored

Execute a measured 20-25% trim of RTX at $189.50 (50% immediately, 50% on bounce to $193-195 within 3-5 sessions) while maintaining 75-80% residual exposure to the structural thesis. Hard stop at $185 on remaining position; pre-committed re-engagement paths include upgrade to Hold on close above $195.80 with RSI>40 and MACD bullish cross, or deep-value reload on flush to $170-180 with RSI sub-30 divergence. Price target $215 over 3-6 months into Q3 2026 earnings.

Outcome

✗

Return

-1.72%

Status

scored

Maintain RTX at 80-85% residual exposure without adding fresh capital, with a pre-committed stop at $192 (just under the 200 SMA at $193.11) and mental stop at $191.50. Upgrade to Overweight with tiered re-engagement triggers at $196.87 (30%), $201.68 (40%), and $207 (30%) on confirmed closes above each level. Downgrade to Underweight with 15-20% trim on confirmed close below $188.

Outcome

–

Return

+0.18%

Status

scored

Execute a measured 15-20% trim of RTX at $194 (50% immediately, 50% on bounce to $198-200) with hard stop at $188.50, while preserving 80-85% residual exposure; upgrade to Hold on confirmed close above $198.50 with RSI reclaiming 40 and MACD flattening, or initiate deep-value reload on flush to $185-172 zone with stabilizing macro and RSI bullish divergence.

Outcome

✗

Return

+0.24%

Status

scored

Execute a 15-20% trim of RTX at ~$193.54 immediately, preserving 80-85% residual exposure given intact structural thesis ($289B backlog, 0.287 beta, $7.45B FCF), with hard stop at $187 on remaining position. Re-engagement conditioned on three event-driven triggers: tactical flush at $185-188 with MACD contraction and RSI divergence, 10 EMA reclaim at $200 on volume >5M, or 50 SMA reclaim at $207.71 on volume >4M—each with staged position sizing from 40% to full Hold upgrade.

Outcome

✗

Return

-1.67%

Status

scored

Initiate Overweight on RTX with front-loaded staged deployment: 40-50% at current levels ($196-197), Tranche 2 (30-40%) on 200 SMA hold confirmation at $192-194 with reversal evidence, and Tranche 3 (20-30%) on either 50 SMA reclaim above $207 or $190 flush with bullish reversal. Full deployment targets 4-5% portfolio weight with hard stop at $188.50. The $289B backlog, 29% YoY EPS growth, 22% net debt reduction, and 0.287 beta defensive characteristics justify conviction sizing despite untested 200 SMA support.

Outcome

✗

Return

+0.68%

Status

scored

Execute a measured 15-20% trim of RTX at $195 (50% immediately, 50% on bounce to $198-200 over 3-5 sessions), preserving 80-85% residual exposure to the structural thesis, with a hard stop at $189.44 and mental stop at $190. The Underweight rating is justified by a bearish MA stack, hostile macro overlay (2007 highs in 10-year, oil above $100, hawkish FOMC risk, late-November CR deadline), and asymmetric catalysts—the bull reversal case requires six independent positive outcomes while the bear case only needs macro to stay hostile. Re-engagement is three-path: tactical flush at $185-188 with RSI divergence, 10 EMA reclaim at $199.75 on volume >5M, or momentum confirmation above $208 on volume >4M.

Outcome

✗

Return

+0.08%

Status

scored

Execute a 25-30% trim of RTX exposure immediately at $195 with a hard stop at $188 on the remaining 70-75% position. The decision is UNDERWEIGHT based on the empirical record showing passive Holds at this configuration decay into -0.4% to -1.1% alpha across five prior cycles, with MACD negative and expanding, RSI at 29.81, and untested 200 SMA at $192.48 representing a knife-edge support level.

Outcome

✓

Return

-1.18%

Status

scored

Maintain HOLD rating on RTX; execute 15-20% trim immediately if above benchmark weight rather than waiting for the $208-210 bounce zone that historically fails at this configuration; stage tactical add at $192.36 (200 SMA) as 40% on first test with $188 hard stop, remaining 60% only on confirmed daily close back above $192 with MACD histogram contracting. Thesis invalidation triggers at $185 on volume >5M, with no hedge recommended given 0.287 beta natural defensive sleeve.

Outcome

✓

Return

-0.22%

Status

scored

Maintain RTX at neutral benchmark weight with Hold rating; the strong Q2 fundamentals (record $24.7B revenue, 28.7% EPS growth, ~$9.9B FCF, $289B backlog) support retaining core exposure, but the broken short-term structure (lower highs, negative MACD at -2.09, RSI at 33, approaching death cross) and thin margin of safety (3% above $192 support, 6% below $209-210 resistance) warrant awaiting a confirmed reversal before upgrading.

Outcome

✓

Return

+0.29%

Status

scored

Maintain an Overweight rating on RTX with a three-tranche staged-buy structure: deploy ~20% of intended weight (~1.0–1.4% of portfolio) immediately at current levels, reserve 35% for a confirmed test of the 200 SMA at $192.07 with bullish reversal confirmation and RSI divergence, and stage the final 35% for a close above $203.87 on volume exceeding 4M shares. Hard stop at $185 (daily close); mental stop on tranche 1 at $190. Full deployment targets 4–5% of portfolio over a 3–6 month horizon, with no hedge recommended due to natural defensive characteristics from the 0.287 beta and $289B backlog cushion.

Outcome

–

Return

-0.63%

Status

scored

Ratify Underweight rating at ~$199 with a measured 30-35% trim of existing RTX exposure executed in tranches over 5-10 sessions, holding 65-70% residual with hard stop at $191.94; no new longs at current levels. Optional 5% notional put hedge at $190 strike Dec 2026 for tail protection against China mineral supply-chain risk. Three independent re-entry paths: momentum confirmation above $207.44 with volume >6M, flush to $172-185 with volume climax reversal, or Q3 2026 beat-and-raise versus $7.86 forward EPS consensus.

Outcome

✓

Return

-0.99%

Status

scored

Maintain RTX at benchmark-weight neutral conviction as the structural floor ($289B backlog, 0.287 beta) prevents selling into support, while broken momentum (below 10 EMA $206.71, 50 SMA $207.21, RSI 35.26, MACD -2.40) precludes adding at $200. Implement a multi-zone framework: Add Zone A at $191-197 on tactical flush signals (RSI <32, MACD contracting, volume declining, 2-3 sessions stabilization above $197); Add Zone B after 4-6 week consolidation above $200 with MACD turning positive and RSI>50; Add Zone C on confirmed close >$215 with consecutive positive MACD days and RSI>50.

Outcome

✓

Return

-0.66%

Status

scored

Maintain Hold at ~$202 as the 9/02 Underweight failure at the same setup ($200 area, broken 50 SMA, MACD widening) demonstrates the structural floor thesis ($289B backlog, $191.67 200 SMA, defensive characteristics) reliably attenuates bearish bets. The discipline-rich framework avoids chasing above $208-210, caps sizing at 2%, and includes pre-committed trim triggers with three-path re-entry framework rather than forcing another failed directional Underweight call.

Outcome

–

Return

+0.67%

Status

scored

Maintain Underweight rating at approximately $200, executing a 30-40% position trim into any relief bounce toward $206-209 (50 SMA/10 EMA confluence zone) within 3-5 sessions, or immediately at current levels if the zone isn't reached; cap RTX at 1.5-2% of portfolio post-trim. Re-enter via three event-driven paths: tactical capitulation bounce to $200-203 with RSI<30, structural base formation above $205 with positive MACD histogram, or momentum confirmation above $215 with consecutive positive MACD days and RSI>50. Hard stop exits residual position on weekly close below 200 SMA at $191.32. Time horizon is tactical 4-8 weeks pending 200 SMA test; revisit structural overweight on confirmed technical repair over 3-6 months.

Outcome

✓

Return

-2.13%

Status

scored

Ratify Underweight at ~$205 with a 20-25% trim executed opportunistically into the $208-211 relief bounce zone, avoiding forced selling at the 50 SMA test ($205.65). Total RTX exposure capped at 1.5-2% of portfolio post-trim, with hard stop at $191 on residual position. Three-path re-entry framework: Path A (flush to $200-203 with capitulation), Path B (4-6 week base above $205 with MACD repair), or Path C (confirmed close >$215 with momentum confirmation).

Outcome

–

Return

-1.24%

Status

scored

Ratify Underweight consensus on RTX at ~$207 with a 25-30% position trim into the $211-215 compression zone, capping exposure at 1.5-1.75% of portfolio; hard stop at $218-220 on remaining position. Three-path re-entry framework covers tactical flush to $200-203 with capitulation, 4-6 week base building above $205, or momentum confirmation above $215 with RSI>50. Near-term price target $215, structural repair target $225, with $191 as floor.

Outcome

✗

Return

-1.88%

Status

scored

Maintain HOLD on RTX at $211.71 as the structural defense case is intact but current entry point offers unfavorable risk-reward (6% upside to $225 vs. 10% downside to $191 200 SMA), with the add trigger set at confirmed close ≤$205 with RSI >40 and no fresh MACD cross below zero. Trim 15-20% on any relief rally to $215-220; hard stop on daily close below $191 (200 SMA).

Outcome

–

Return

-0.17%

Status

scored

Maintain Overweight rating with a disciplined split-deployment framework that defers initial entry to technical confirmation gates, scaling in Tranche A on a pullback to $205-207 with MACD stabilization, Tranche B on reclaim above $214.50 with RSI>50, capped at 1-3% portfolio weight with hard stop at $203.50.

Outcome

✓

Return

+0.04%

Status

scored

Ratifying the HOLD consensus at ~$212 maintains the existing 2-3% core position without adding capital given the "decision support" setup (MACD histogram at -2.40 and expanding, price hugging lower Bollinger Band). The framework adopts the neutral analyst's conditional add triggers—a confirmed close above $214.50 with MACD histogram turning less negative, or a pullback to $190-195 zone—while rejecting both the aggressive 4-5% Overweight sizing and the conservative pure-Hold with no tactical criteria.

Outcome

✓

Return

+0.81%

Status

scored

Overweight rating is ratified on RTX as the structural thesis (backlog conversion, FCF inflection, sole-source franchises) is verified and uncontested, while the trader's Tranche A trigger at $207-209 is moved behind momentum confirmation gates per the 8/24 lesson to avoid the "decision support" setup that produced only +0.2% alpha last cycle. Hard stop remains at daily close below $204, with near-term price target $225 and extended target $240.

Outcome

✓

Return

+0.51%

Status

scored

Initiate RTX at $208.50 as a split-deployment Overweight, deploying 2.5–3.0% initially while reserving 1.5–2.0% for Tranche 2 pending confirmed close above $216.21 with MACD histogram turning positive; hard stop at $203.28 protects against the $190 bear-case target while the $289B backlog and 0.29 defensive beta support the structural long thesis toward $225–240.

Outcome

✓

Return

-0.33%

Status

scored

Trim RTX to 85% of position weight (15% reduction) at decision date rather than relying on layered triggers. Hard stop at $202 (50 SMA, ~2x ATR), full exit below $190 (200 SMA structural floor), with re-entry triggered at $217.76 on volume >5M, RSI>55, and positive MACD histogram confirmation.

Outcome

✓

Return

-1.12%

Status

scored

Trim RTX to approximately 70-75% of benchmark weight in the A&D sleeve, rejecting both the Aggressive analyst's full exit recommendation and the Conservative analyst's overweight framing. Implement hard stops at $202 (50 SMA/2x ATR) and full exit on close below $210.85 with volume >5M; re-entry trigger at $220 with volume >4.5M shares. The asymmetric risk profile (upside to $227 = +6.9%, downside to $202 = -4.8%, downside to $190 = -10.5%) and technical deterioration (10 EMA rollover, MACD bearish cross, RSI 48) warrant reduced exposure despite acknowledged structural bull case catalysts.

Outcome

✗

Return

-3.66%

Status

scored

Maintain a HOLD rating at ~$220 as the structural case (Q2 2026 operating leverage with revenue +14.5%, operating income +30.7%, EPS +28.7%; $22.9B Tomahawk contract extending revenue visibility through 2033; $80B+ backlog) remains intact but valuation is stretched at 38.8x TTM P/E and 28x forward P/E with hostile macro headwinds including 30Y yields at 2007 highs and Iran de-escalation compressing defense premium. Adopt a tiered entry framework (50% at $209-213, 50% at $205-208 on broader market selloff) with a mandatory 5-session checkpoint—if neither trigger fires, trim 10-15% to neutral weight to prevent the passive-decay pattern identified in the 8/18 lesson.

Outcome

✗

Return

-2.28%

Status

scored

Ratify HOLD at ~$225 given stretched momentum (RSI 71.7, MACD histogram -0.40, price at 78% of Bollinger Band range) and a tepid 1% reaction to the $22.9B Tomahawk contract. Adopt the Neutral analyst's tiered add plan: 10-15% of position at $221-$222 on confirmed support with decelerating MACD histogram, and another 10-15% at $217-$218 on volume confirmation. Hard stop at $199.50 (50 SMA region) with a trailing stop at 10 EMA minus 1 ATR (~$216 currently). A 5-session checkpoint is non-negotiable: if neither entry trigger fires within 5 trading days, trim 10-15% of position to neutral weight to address the recurring passive-decay pattern.

Outcome

✓

Return

+1.74%

Status

scored

Maintain HOLD rating at $221.64 without chasing the current level. Adopt a disciplined layered entry framework: 25% of incremental exposure at $215–$218 with MACD histogram deceleration, 30% at $199–$205 on 50 SMA hold confirmation, and 20% on confirmed close above $226.88 with volume ≥5M. A non-negotiable 5-session checkpoint requires trimming 10–15% to neutral weight if neither trigger fires, addressing the documented decay pattern from five prior Hold calls.

Outcome

✓

Return

-0.60%

Status

scored

The three-way analyst debate converges on HOLD for RTX, citing genuine structural improvements (revenue $67B→$93.5B, margins 5.2%→12.7%, FCF $3.92B→$9.88B) alongside unfavorable technical setup (RSI 70, bearish MACD cross, declining volume on retests); the asymmetric risk favors the bull's $240–260 target requiring multiple tailwinds versus bear's downside requiring only one disappointment. The framework enforces time-bounded discipline: strict add zone $213–$218 (rejecting 10 EMA at $220.64), confirmed breakout trigger above $225 with volume >7M and MACD positive re-cross, 7-session expiration forcing 10–15% trim to neutral if neither triggers fire, and hard stop at $210.

Outcome

✓

Return

+1.13%

Status

scored

Maintain RTX at current weight with a HOLD rating as $220.48 presents unfavorable 0.65:1 risk/reward given cooling technical momentum (MACD below signal, RSI 67.41). Execute via opportunistic scale-in at defined technical levels ($215 and $213) with hard stops, and add on confirmed breakout above $224.12 with volume and momentum confirmation; if neither trigger fires within 5 sessions, trim to neutral weight to prevent passive decay.

Outcome

✓

Return

-1.02%

Status

scored

Maintain RTX at Hold with no additions at $222.76; scale in via a three-tranche structure (30% at $217.50, 30% at $215, 40% reserved for $212 if 10 EMA fails) on pullback, or add with standard sizing on confirmed breakout above $226.88 with volume exceeding 5M shares.

Outcome

✓

Return

-0.49%

Status

scored

Maintain RTX exposure with an active HOLD framework. Trail stop to $215 to lock in gains while avoiding the overbought $223.86 entry (RSI 76, 79% volume collapse), and engage only on the $215–$219 primary entry zone or a deeper $210–$212 secondary zone within 10 trading days; if neither triggers, re-evaluate with a 3–6 month $240+ target.

Outcome

✓

Return

-0.12%

Status

scored

Maintain RTX exposure with a trailing stop at $214 while avoiding new positions above $220, engaging only on a pullback to the $215-218 zone (starter sizing 30-50% of intended weight, hard stop $209) or a confirmed breakout above $227 with volume above 5M shares, closing print confirmation, and MACD stabilization. The HOLD rating balances intact structural thesis (sole-source franchises, NATO commitments, $9.9B FCF) against tactical overbought conditions (RSI 76.77, MACD histogram compressed to 0.81, volume declining to 3.28M).

Outcome

–

Return

+0.49%

Status

scored

The recommendation is Overweight (BUY), implemented via a phased approach due to overbought conditions at entry. Initiate a half-sized core position at $222.50 (1.5–2% of portfolio) with a hard stop at $194.84 (50 SMA), reserving dry powder for $208–213 add tranches on pullback, and reserving full target weight (3–4%) only on confirmed hold above the 50 SMA with MACD re-acceleration. Structural conviction (Q2 +14.5% revenue, +31% operating income, $8B debt reduction, multiple catalysts) supports meaningful exposure, but the entry point—overbought RSI 75.95, declining MACD histogram, lowest-volume buying climax—warrants the phased approach over full commitment.